Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer

Georgina G Kingshott*, Kalina M Biernacka*, Alex W Sewell, Rachel M Barker, Hanna A Zielinska, Kathryn Mccarthy, Richard M Martin, J. Athene Lane, Edward Rowe, Jon Oxley, Jeff M. P. Holly, Claire M Perks

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

8 Downloads (Pure)


Prostate cancer is the second major cause of male cancer deaths. Obesity, type 2 diabetes, and cancer risk are linked. Insulin-like growth factor II (IGF-II) is involved in numerous cellular events, including proliferation and survival. The IGF-II gene shares its locus with the lncRNA, H19. IGF-II/H19 was the first gene to be identified as being ‘imprinted’ – where the paternal copy is not transcribed – a silencing phenomenon lost in many cancer types. We disrupted im-printing behaviour in vitro by altering metabolic conditions and quantified it using RFLP, qPCR and pyrosequencing; changes to peptide were measured using RIA. Prostate tissue samples were analysed using ddPCR, pyrosequencing and IHC. We compared with in silico data, provided by TGCA on the cBIO Portal. Disruption of imprinting behaviour, in vitro, occurs at the molecular level with no changes to peptide. In vivo, most specimens retained imprinting status apart from a small subset which showed reduced imprinting. A positive correlation was seen between IGF-II and H19 mRNA expression, which concurred with findings of larger Cancer Genome Atlas (TGCA) cohorts. This positive correlation did not affect IGF-II peptide. Type 2 diabetes and / or obesity directly affect regulation growth factors involved in carcinogenesis.
Original languageEnglish
Article number825
Number of pages18
Issue number4
Publication statusPublished - 16 Feb 2021

Structured keywords

  • ICEP


  • IGF2
  • H19
  • imprinting
  • cancer
  • inflammatory markers

Cite this